Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by (1,049)

Items 701–800 of 1,049

1. EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib
   Jean‐Nicolas Gallant, Jonathan H. Sheehan, Timothy M. Shaver, Mark Bailey, Doron Lipson, Raghu Chandramohan, Monica Red Brewer, Sally Jane York, Mark G. Kris, Jennifer A. Pietenpol et al. · 2015 · Cancer Discovery
2. The Evolution of Therapies in Non-Small Cell Lung Cancer
   Vishal Boolell, Muhammad Alamgeer, D. Neil Watkins, Vinod Ganju · 2015 · Cancers
3. Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells
   Kammei Rai, Nagio Takigawa, Sachio Ito, Hiromi Kashihara, Eiki Ichihara, Tatsuji Yasuda, Kenji Shimizu, Mitsune Tanimoto, Katsuyuki Kiura · 2011 · Molecular Cancer Therapeutics
4. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
   Jänne, Pasi A, Ou, Sai-Hong I, Kim, Dong-Wan, Oxnard, Geoffrey R, Martins, Renato, Kris, Mark G, Dunphy, Frank, Nishio, Makoto, O'Connell, Joseph, Paweletz, Cloud et al. · 2014 · The Lancet Oncology
5. Predicting who will have asthma at school age among preschool children
   Olga E.M. Savenije, Marjan Kerkhof, Gerard H. Koppelman, Dirkje Sjoukje Postma · 2012 · Journal of Allergy and Clinical Immunology
6. Oncologists’ and cancer patients’ views on whole-exome sequencing and incidental findings: results from the CanSeq study
   Stacy W. Gray, Elyse Richelle Park, Julie Najita, Yolanda Martins, Lara N. Traeger, Elizabeth F. Bair, Joshua J. Gagne, Judy Ellen Garber, Pasi Antero Janne, Neal Ian Lindeman et al. · 2016 · Genetics in Medicine
7. Precision Oncology Medicine: The Clinical Relevance of Patient‐Specific Biomarkers Used to Optimize Cancer Treatment
   Keith Thomas Schmidt, Cindy H. Chau, Douglas K. Price, William Douglas Figg · 2016 · The Journal of Clinical Pharmacology
8. Role of epidermal growth factor receptor in lung cancer and targeted therapies.
   Tiecheng Liu, Xin Jin, Yan Wang, Ke Wang · 2017 · Europe PMC (PubMed Central)
9. Statistical Considerations for Subgroup Analyses
   Wang Xiaofei, Steven Piantadosi, Jennifer G. Le‐Rademacher, Sumithra J. Mandrekar · 2020 · Journal of Thoracic Oncology
10. Traf2- and Nck-Interacting Kinase Is Essential for Wnt Signaling and Colorectal Cancer Growth
    Miki Shitashige, Reiko Satow, Takafumi Jigami, Kazunori Aoki, Kazufumi Honda, Tatsuhiro Shibata, Masaya Ono, Setsuo Hirohashi, Tesshi Yamada · 2010 · Cancer Research
11. EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
    Alberto Antonicelli, Stefano Cafarotti, Alice Indini, Alessio Galli, Andrea Russo, Alfredo Cesario, Filippo Lococo, Patrizia Russo, Alberto Franco Mainini, Luca Giuseppe Bonifati et al. · 2013 · International Journal of Medical Sciences
12. Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer
    Matthew B. Schabath, William Douglas Cress, Teresita Muñoz-Antonia · 2016 · Cancer Control
13. Toward automatic prediction of EGFR mutation status in pulmonary adenocarcinoma with 3D deep learning
    Wei Zhao, Jiancheng Yang, Bingbing Ni, Dexi Bi, Yingli Sun, Mengdi Xu, Xiaoxia Zhu, Cheng Li, Liang Jin, Pan Gao et al. · 2019 · Cancer Medicine
14. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
    Michael Juchum, Marcel Günther, Stefan Laufer · 2015 · Drug Resistance Updates
15. Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)
    Thanyanan Reungwetwattana, Saravut John Weroha, Julian R. Molina · 2011 · Clinical Lung Cancer
16. Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer
    Victor Ho-Fun Lee, Vicky Pui‐Chi Tin, Tim‐Shing Choy, Ka On Lam, Cheuk‐Wai Choi, Lap-Ping Chung, Janice Wing Hang Tsang, Patty Ho, Dennis Kwok‐Chuen Leung, Edmond S.K. Ma et al. · 2013 · Journal of Thoracic Oncology
17. Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens
    Carlie Sigel, Andre Luis Moreira, William David Travis, Maureen Frances Zakowski, Raymond H. Thornton, Gregory J. Riely, Natasha Rekhtman · 2011 · Journal of Thoracic Oncology
18. Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review
    Julien Péron, Denis Maillet, Hui Kong Gan, Eric Xueyu Chen, Benoît You · 2013 · Journal of Clinical Oncology
19. Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention
    Baldeep Pabla · 2015 · World Journal of Clinical Oncology
20. Skin problems and EGFR-tyrosine kinase inhibitor
    Toshiyuki Kozuki · 2016 · Japanese Journal of Clinical Oncology
21. A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization
    Thomas A. Hensing, Apoorva Chawla, Rishi Batra, Ravi Salgia · 2013 · Advances in experimental medicine and biology
22. EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
    Niki Karachaliou, Manuel Fernández-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell · 2018 · Translational Cancer Research
23. Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation
    Tatsuya Yoshida, Genichiro Ishii, Kōichi Goto, Shinya Neri, Hiroko Hashimoto, Kiyotaka Yoh, Seiji Niho, Shigeki Umemura, Shingo Matsumoto, Hironobu Ohmatsu et al. · 2014 · Clinical Cancer Research
24. EGFR Blockade Enriches for Lung Cancer Stem–like Cells through Notch3-Dependent Signaling
    Rajeswara Rao Arasada, Joseph M. Amann, Mohammad Aminur Rahman, Stacey S. Huppert, David Paul Carbone · 2014 · Cancer Research
25. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With<i>EGFR</i>-Mutated Advanced Non–Small Cell Lung Cancer
    Aguiar, Pedro N., Haaland, Benjamin, Park, Wungki, San Tan, Pui, del Giglio, Auro, de Lima Lopes, Gilberto · 2018 · JAMA Oncology
26. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
    Talal Hilal, Mohamad Bassam Sonbol, Vinay K. Prasad · 2019 · JAMA Oncology
27. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With AdvancedEGFR-Mutant Non–Small Cell Lung Cancer
    Thomas E. Stinchcombe, Pasi Antero Janne, Xiaofei Wang, Erin Marie Bertino, Jared M. Weiss, Lyudmila A. Bazhenova, Lin Gu, Christie J. Lau, Cloud Peter Paweletz, Anthony John Jaslowski et al. · 2019 · JAMA Oncology
28. Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
    Yuan Cheng, Tao Zhang, Qing Xu · 2021 · MedComm
29. SurvSHAP(t): Time-dependent explanations of machine learning survival models
    Mateusz Krzyziński, Mikołaj Spytek, Hubert Baniecki, Przemysław Biecek · 2022 · Knowledge-Based Systems
30. Targeted therapy for non-small-cell lung cancer: past, present and future
    Patrick M. Forde, David S. Ettinger · 2013 · Expert Review of Anticancer Therapy
31. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
    Susan E. Jorge, Susumu S. Kobayashi, Daniel Botelho Costa · 2014 · Brazilian Journal of Medical and Biological Research
32. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer
    Yixiang Mao, Wei Li, Kai Chen, Yufeng Xie, Qiang Liu, Min Yao, Weiming Duan, Xiumin Zhou, Rongrui Liang, Min Tao · 2014 · Oncotarget
33. State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine
    Mizuki Nishino, Hiroto Hatabu, Bruce Evan Johnson, Theresa C. McLoud · 2014 · Radiology
34. FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
    Isabelle Solassol, Frédéric Pinguet, Xavier Quantin · 2019 · Biomolecules
35. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
    Valerio Gristina, Umberto Malapelle, Antonio Galvano, Pasquale Pisapia, Francesco Pepe, Christian Diego Rolfo, Silvia Tortorici, Viviana Bazan, Giancarlo Troncone, Antonio Dello Russo · 2020 · Cancer Treatment Reviews
36. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
    Yuankai Shi, Xingsheng Hu, Shucai Zhang, Dongqing Lv, Lin Wu, Qitao Yu, Yiping Zhang, Li Liu, Xiang Wang, Ying Cheng et al. · 2021 · The Lancet Respiratory Medicine
37. The impact of the Cancer Genome Atlas on lung cancer
    Jeremy T.-H. Chang, Yee Ming Lee, R. Stephanie Huang · 2015 · Translational research
38. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis
    Marie E. Westwood, Manuela A. Joore, Penny F. Whiting, Antoinette D. I. van Asselt, Bram L. T. Ramaekers, Nigel Armstrong, Kate Misso, Johan Louis Severens, Jos Kleijnen · 2014 · Health Technology Assessment
39. Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
    Yelena Yuriy Janjigian, Christopher G. Azzoli, Lee M. Krug, Leanne K. Pereira, Naiyer A. Rizvi, Maria Catherine Pietanza, Mark G. Kris, Michelle S. Ginsberg, William J. Pao, Vincent A. Miller et al. · 2011 · Clinical Cancer Research
40. The clinical utility of tumor mutational burden in non-small cell lung cancer
    Laurent Greillier, Pascale Tomasini, Fabrice Barlési · 2018 · Translational Lung Cancer Research
41. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
    Petrelli, Nicholas J., Winer, Eric P., Brahmer, Julie, Dubey, Sarita, Smith, Sonali, Thomas, Charles, Vahdat, Linda T., Obel, Jennifer, Vogelzang, Nicholas, Markman, Maurie et al. · 2009 · Journal of Clinical Oncology
42. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
    Chen, G., Feng, J., Zhou, C., Wu, Y.-L., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S. et al. · 2013 · Annals of Oncology
43. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
    Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S. et al. · 2015 · Drugs
44. Large‐scale comparative analyses of immunomarkers for diagnostic subtyping of non‐small‐cell lung cancer biopsies
    Arne Warth, Thomas Muley, Esther Herpel, Michael A. Meister, Felix J.F. Herth, Peter Schirmacher, Wilko Weichert, Hans Hoffmann, Philipp Albert Schnabel · 2012 · Histopathology
45. Optimizing Endobronchial Ultrasound for Molecular Analysis. How Many Passes Are Needed?
    Lonny B. Yarmus, Jason Akulian, Christopher R. Gilbert, David J Feller-Kopman, Hans J. Lee, Paul Zarogoulidis, Noah Lechtzin, Syed Zulfiqar Ali, Vidya Sathiyamoorthy · 2013 · Annals of the American Thoracic Society
46. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients
    Monic Roengvoraphoj, Gregory J. Tsongalis, Konstantin H. Dragnev, James R. Rigas · 2013 · Cancer Treatment Reviews
47. Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment
    Reinhard Buettner, Jürgen Wolf, Roman Kurt Thomas · 2013 · Journal of Clinical Oncology
48. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
    Jeffrey P. Gregg, Tianhong Li, Ken Y. Yoneda · 2019 · Translational Lung Cancer Research
49. A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed
    Shuncong Wang, Yewei Liu, Yuanbo Feng, Jian Zhang, Johannes V. Swinnen, Yue Li, Yicheng Ni · 2019 · Cancers
50. Cigarette Smoke-Induced Respiratory Response: Insights into Cellular Processes and Biomarkers
    Sang-Ryul Cha, Jimin Jang, Sung‐Min Park, Se Min Ryu, Seong-Joon Cho, Se‐Ran Yang · 2023 · Antioxidants
51. Pack‐years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer
    Yelena Yuriy Janjigian, Kevin McDonnell, Mark G. Kris, Ronglai Shen, Camelia S. Sima, Peter Brian Bach, Naiyer A. Rizvi, Gregory J. Riely · 2009 · Cancer
52. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
    Marie Brevet, Melissa Lynne Johnson, Christopher G. Azzoli, Marc Ladanyi · 2010 · Lung Cancer
53. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
    Mark Agulnik, Nelson, Ziehr, J R Johnson · 2013 · OncoTargets and Therapy
54. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study
    Julien Mazières, Wolfram Brugger, Federico Cappuzzo, Peter Middel, Alice Frosch, Ilze Bāra, Gaëlle Klingelschmitt, Barbara Klughammer · 2013 · Lung Cancer
55. A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer
    Manabu Soda, Kazutoshi Isobe, Akira Inoue, Makoto Maemondo, Satoshi Oizumi, Yuka Fujita, Akihiko Gemma, Yoshihiro Yamashita, Toshihide Ueno, Kengo Takeuchi et al. · 2012 · Clinical Cancer Research
56. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials
    Paul Wheatley‐Price, Fiona Helen Blackhall, Siow Ming Lee, Clement Ma, Linda Ashcroft, Mark Jitlal, Wendi Qian, Allan K. Hackshaw, Robin Rudd, Richard Booton et al. · 2010 · Annals of Oncology
57. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)
    Rabab Mohamed Gaafar, Veerle F.M. Surmont, Giorgio V. Scagliotti, Rob J. van Klaveren, Demetris Papamichael, John J. Welch, Baktiar Hasan, Valter Torri, Jan P. van Meerbeeck · 2011 · European Journal of Cancer
58. Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
    Fred R. Hirsch, Pasi Antero Janne, Wilfried Eberhardt, Federico Cappuzzo, N. Thatcher, Robert Pirker, Hak Choy, Edward S. Kim, Luis G Paz-Ares, David R. Gandara et al. · 2013 · Journal of Thoracic Oncology
59. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer
    Emma Pailler, Nathalie Auger, Colin R. Lindsay, Philippe R. Vielh, A. Islas-Morris-Hernandez, Isabelle Borget, Maud Ngo‐Camus, David Planchard, Jean‐Charles Soria, Benjamin Besse et al. · 2015 · Annals of Oncology
60. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
    Lynn T. Tanoue · 2011 · Yearbook of Pulmonary Disease
61. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma
    Yang Qu, Katsura Emoto, Takashi Eguchi, Rania Gaber Mohamed Aly, Hua Zheng, Jamie E. Chaft, Kay See Tan, David Randolph Jones, Mark G. Kris, Prasad S. Adusumilli et al. · 2018 · Journal of Thoracic Oncology
62. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Current Cancer Drug Targets
63. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
    Wenfeng Fang, Yihua Huang, Shaodong Hong, Zhonghan Zhang, Minghui Wang, Jiadi Gan, Wenjing Wang, Honglin Guo, Kai Wang, Li Zhang · 2019 · BMC Cancer
64. Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations
    Yasufumi Kato, Nir Peled, Murry W. Wynes, Koichi Yoshida, Marta Pardo, Céline Mascaux, Tatsuo Ohira, Masahiro Tsuboi, Jun Matsubayashi, Toshitaka Nagao et al. · 2010 · Journal of Thoracic Oncology
65. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    Alice Tsang Shaw, Anna M. Varghese, Benjamin Solomon, Daniel Botelho Costa, Silvia Novello, Mari A. Mino-Kenudson, Mark Magdi Awad, Jeffrey A. Engelman, Gregory J. Riely, Valentina Monica et al. · 2012 · Annals of Oncology
66. Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic Sequencing
    Shinji Kohsaka, Mark P. Petronczki, Flavio Solca, Makoto Maemondo · 2018 · Future Oncology
67. EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?
    Lizza E.L. Hendriks, Egbert Frederik Smit, Bettine A.H. Vosse, Wouter Willem Mellema, Daniëlle A.M. Heideman, Gerben P Bootsma, Marcel Westenend, Cordula C. M. Pitz, Geeuwke Jan de Vries, Ruud M A Houben et al. · 2014 · Lung Cancer
68. A Novel Classification of Lung Cancer into Molecular Subtypes
    Lisandra E. West, Smruti J. Vidwans, Nicholas Paul Campbell, Jeff Shrager, George R. Simon, Raphael Bueno, Phillip A. Dennis, Gregory A. Otterson, Ravi Salgia · 2012 · PLoS ONE
69. Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation
    Yoshihiko Fujita, Kenichi Suda, Hideharu Kimura, Kazuko Matsumoto, Tokuzo Arao, Tomoyuki Nagai, Nagahiro Saijo, Yasushi Yatabe, Tetsuya Mitsudomi, Kazuto Nishio · 2012 · Journal of Thoracic Oncology
70. Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications
    Marco Gerlinger, James W.F. Catto, Torben Falck Orntoft, Francisco X. Real, Ellen C. Zwarthoff, Charles Swanton · 2014 · European Urology
71. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer
    Gerlinde Pilkington, Angela Boland, Tamara J. Brown, James Oyee, A Bagust, Rumona Dickson · 2015 · Thorax
72. Molecular Pathology of Non–Small Cell Lung Cancer
    Dara L. Aisner, Carrie B. Marshall · 2012 · American Journal of Clinical Pathology
73. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
    David König, Spasenija Savic Prince, Sacha I. Rothschild · 2021 · Cancers
74. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers
    Jinfeng Yu, Tong Fang, Chengyu Yun, Xue Liu, Xiaoqing Cai · 2022 · Frontiers in Molecular Biosciences
75. The Oncogenic Lung Cancer Fusion Kinase CD74-ROS Activates a Novel Invasiveness Pathway through E-Syt1 Phosphorylation
    Hyun Jung Jun, Hannah Johnson, Roderick Terry Bronson, Sébastien M. de Feraudy, Forest M. White, Alain Charest · 2012 · Cancer Research
76. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
    Becker, A., Crombag, L., Heideman, D.A.M., Thunnissen, F.B., van Wijk, A.W., Postmus, P.E., Smit, E.F. · 2011 · European Journal of Cancer
77. Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
    Hua Shen, Fang Zhu, Jinyuan Liu, Tongpeng Xu, Dong Pei, Rong Wang, Yingying Qian, Qi Li, Lin Wang, Zhumei Shi et al. · 2014 · PLoS ONE
78. EGFR Mutation Status in Primary Lung Adenocarcinomas and Corresponding Metastatic Lesions: Discordance in Pleural Metastases
    Hye‐Suk Han, Dae‐Woon Eom, Joo Heon Kim, Kyung‐Hee Kim, Hyang-Mi Shin, Jin Young An, Ki Man Lee, Kang Hyeon Choe, Ki Hyeong Lee, Seung Taik Kim et al. · 2011 · Clinical Lung Cancer
79. Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status
    Idris Bahce, Egbert Frederik Smit, Mark Lubberink, Astrid A.M. van der Veldt, Maqsood M. Yaqub, Albert D. Windhorst, Robert C. Schuit, Erik Thunnissen, Daniëlle A.M. Heideman, Pieter E. Postmus et al. · 2012 · Clinical Cancer Research
80. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
    David Lok Hang Chan, Eva Segelov, Rachel SH Wong, Annabel Smith, Rebecca A. Herbertson, Bob T. Li, Niall Christopher Tebbutt, Timothy Jay Price, Nick Pavlakis · 2017 · Cochrane Database of Systematic Reviews
81. The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
    Priyanka H. Patel, David A. Palma, Fiona McDonald, Alison Claire Tree · 2019 · Clinical Oncology
82. Lung cancer molecular epidemiology in China: recent trends.
    Caicun Zhou · 2014 · Europe PMC (PubMed Central)
83. Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer
    Ying Li, Li Y, Tong Yang, Sen Wei, Jing Wang, Min Wang, Yuli Wang, Qinghua Zhou, Hongyu Liu, Jun Chen · 2013 · PLoS ONE
84. Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens
    Silvia Querings, Janine Altmüller, Sascha Ansén, Thomas Zander, Danila Seidel, Franziska Gabler, Martin Peifer, Eva Markert, KATHRYN C. STEMSHORN, Bernd Timmermann et al. · 2011 · PLoS ONE
85. EGFR,KRAS,BRAFandALKgene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype
    Arne Warth, Roland Penzel, Heike Lindenmaier, Regine Brandt, Albrecht Stenzinger, Esther Herpel, Benjamin Frank Goeppert, Michael Thomas, Felix J.F. Herth, Hendrik Dienemann et al. · 2013 · European Respiratory Journal
86. In Vivo Inhibition of RIPK2 Kinase Alleviates Inflammatory Disease
    Justine T. Tigno-Aranjuez, Pascal Benderitter, Frederik J. R. Rombouts, Frederik D. Deroose, Xiaodong Bai, Benedetta Mattioli, Fabio Cominelli, Theresa T. Pizarro, Jan Hoflack, Derek W. Abbott · 2014 · Journal of Biological Chemistry
87. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
    Richard W. Bayliss, Jene Choi, Dean Anthony Fennell, Andrew M. Fry, Mark W. Richards · 2016 · Cellular and Molecular Life Sciences
88. Liquid Biopsy and Lung Cancer
    Pasquale Pisapia, Umberto Malapelle, Giancarlo Troncone · 2018 · Acta Cytologica
89. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
    Shuyu Huang, Sander M. J. van Duijnhoven, Alice J.A.M. Sijts, Andrea van Elsas · 2020 · Journal of Cancer Research and Clinical Oncology
90. Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings
    Harvey, R Donald, Adams, Val R, Beardslee, Tyler, Medina, Patrick · 2020 · Journal of Oncology Pharmacy Practice
91. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
    Keam, Bhumsuk, Kim, Dong-Wan, Park, Jin Hyun, Lee, Jeong-Ok, Kim, Tae Min, Lee, Se-Hoon, Chung, Doo Hyun, Heo, Dae Seog · 2014 · International Journal of Clinical Oncology
92. EGFR gene status in cytological samples of nonsmall cell lung carcinoma
    Gilda da Cunha Santos, Mauro Ajaj Saieg, William Robert Geddie, Natasha B. Leighl · 2011 · Cancer Cytopathology
93. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
    Yongsheng Wang, Gerald Schmid‐Bindert, Caicun Zhou · 2011 · Therapeutic Advances in Medical Oncology
94. New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response
    Jessica Menis, Baktiar Hasan, Benjamin Besse · 2014 · European Respiratory Review
95. MicroRNA-214 Regulates the Acquired Resistance to Gefitinib via the PTEN/AKT Pathway in EGFR-mutant Cell Lines
    Yong-Sheng Wang, Yinhua Wang, Hongping Xia, Songwen Zhou, Gerald Schmid‐Bindert, Caicun Zhou · 2012 · Asian Pacific Journal of Cancer Prevention
96. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
    Conor Ernst Steuer, Madhusmita Behera, Lynne D. Berry, Sungjin Kim, Michael R. Rossi, Gabriel Sica, Taofeek Kunle Owonikoko, Bruce Evan Johnson, Mark G. Kris, Paul A. Bunn et al. · 2015 · Cancer
97. Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis
    Ray Lin, Ji Lin, Satrajit Roychoudhury, Keaven M. Anderson, Tianle Hu, Bo Huang, Larry F Leon, Jason J.Z. Liao, Rong Liu, Xiaodong Luo et al. · 2019 · Statistics in Biopharmaceutical Research
98. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA
    Chae, Young Kwang, Davis, Andrew A., Carneiro, Benedito A., Chandra, Sunandana, Mohindra, Nisha, Kalyan, Aparna, Kaplan, Jason, Matsangou, Maria, Pai, Sachin, Costa, Ricardo et al. · 2016 · Oncotarget
99. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study
    Karampeazis, Athanasios, Voutsina, Alexandra, Souglakos, John, Kentepozidis, Nikos, Giassas, Stelios, Christofillakis, Charalambos, Kotsakis, Athanasios, Papakotoulas, Pavlos, Rapti, Ageliki, Agelidou, Maria et al. · 2013 · Cancer
100. Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer
     Shirish M. Gadgeel, Antoinette J. Wozniak · 2013 · Clinical Lung Cancer